L-Valine (CAS 72-18-4, C₅H₁₁NO₂, molar mass 117.15 g/mol) is supplied as a white to off-white crystalline powder with a pharmacopoeial assay range of 98.5–101.5 % on the dried basis. The product line includes L-Valine Feed Grade, L-Valine USP/FCC, L-Valine AJI92, and L-Valine High-Density Cell Culture Grade. These designations differ by endotoxin loading, heavy-metal and microbial limits, residual solvent profile, particle morphology, and packaging, not by the primary chemical structure. L-Valine is the L-enantiomer of 2-amino-3-methylbutanoic acid and is produced by direct fermentation of maize- or sugar beet-derived glucose with non-sporulating Corynebacterium glutamicum strains, followed by ultrafiltration, cation-exchange chromatography, activated-carbon decoloration, crystallization, and fluidized-bed drying.

The product is used in four distinct application groups: parenteral amino acid infusions, chemically defined cell culture media, clinical and sports nutrition powders, and animal feed premixes. In food applications, L-valine is listed as a direct food substance for nutritional purposes under 21 CFR 172.320. Unlike synthetic DL-valine, the fermentation-derived L-valine product has an L-enantiomer content of at least 99.0 % and avoids the racemate fraction that contributes little to mammalian nitrogen metabolism. The primary comparator branched-chain amino acids are L-leucine and L-isoleucine, but valine is distinct in being glucogenic through succinyl-CoA, whereas leucine is ketogenic and isoleucine is mixed glucogenic and ketogenic.

What Limits Direct Substitution of L-Valine in Parenteral Nutrition Compounding?

Direct substitution into ternary admixtures is constrained by solubility, sterilization stability, and compatibility with reducing sugars. L-Valine exhibits a water solubility of approximately 88 g/L at 25 °C, which is sufficient for standard crystalline amino acid solutions but becomes limiting when high-concentration all-in-one admixtures are stored at 2–8 °C. The product should not be autoclaved in the presence of dextrose or fructose because the α-amino group undergoes Maillard browning and Amadori-compound formation when heat sterilization is applied to high-energy admixtures. The parenteral grade is tested for bacterial endotoxins according to USP <85> with a typical acceptance criterion of ≤0.5 EU/mg.

Infusion compounding operations target a pH of 5.5–7.0 after dilution. Outside this window the zwitterionic buffering capacity of valine is low, and pH adjustment should be carried out with acetic acid or sodium hydroxide rather than phosphate buffers to avoid precipitation of divalent metal phosphates. Trace-element incompatibility with iron and copper salts should be evaluated in total parenteral nutrition admixtures because weak amino acid chelation can alter visible particulate stability. The dry injectable grade is not added directly to lipid emulsions due to phase destabilization risk.

Release testing under a current USP/FCC certificate of analysis includes assay by HPLC or non-aqueous titration, specific rotation, loss on drying, residue on ignition, chloride, sulfate, iron, heavy metals, and microbial enumeration. For injectable and cell culture grades, bacterial endotoxin testing is mandatory. The table below summarizes representative acceptance criteria and associated compendial methods.

Feed-grade material may be specified with an assay of ≥98.5 % and with elemental impurity limits aligned to regional animal feed regulations. Published data for specific geographic limit harmonization remains limited, and customer-specific certificates of analysis should be consulted.

Fermentation-Derived L-Valine and Downstream Crystallization Controls

Industrial fermentation uses a high-producing strain derived from Corynebacterium glutamicum or a similar production host, with carbon source feeding controlled by dissolved oxygen and respiratory quotient. The process window is maintained at 35–37 °C and pH 6.8–7.2; pH is corrected with ammonia, which also supplies nitrogen. Fermentation broths typically contain L-alanine, L-leucine, and α-ketoisovalerate as minor metabolites. Downstream recovery includes ultrafiltration of whole broth, cation-exchange chromatography at low pH, ammonia elution, activated carbon treatment, concentration, cooling crystallization, and fluidized-bed drying. Product temperature during drying is kept below 80 °C to avoid discoloration and polymorphic transition.

Critical process parameters in crystallization are cooling rate and seed crystal surface area. Uncontrolled fast cooling produces fine needles with poor filtration and low tapped density, which can affect dry blending homogeneity. Batch-to-batch variation in tapped density is typically controlled between 0.35 g/cm³ and 0.55 g/cm³ for the standard crystalline grade; granulated feed-grade forms are available to reduce dust formation in twin-ribbon and paddle mixers. Enantiomeric purity is monitored by chiral HPLC and is typically controlled at ≥99.0 % L-enantiomer. Residual fermentation by-products are limited by TLC or HPLC fingerprinting against a reference standard.

Standard package configurations include 25 kg double-layer polyethylene bags inside fibre drums, 500 kg or 1,000 kg flexible intermediate bulk containers for feed grade, and 1 kg or 5 kg low-extractable polyethylene bottles for cell culture grade. The product is assigned a shelf life of 24 months when stored in unopened containers at 25 °C and protected from light. Injectable-grade containers should be resealed under inert gas after opening if not consumed immediately.

When L-Valine Replaces L-Leucine or L-Isoleucine in BCAA-Enriched Formulations

Replacement is not stoichiometrically equivalent because transport competition and metabolic fate differ. L-Valine, L-leucine, and L-isoleucine are absorbed via system L amino acid transporters and share the branched-chain aminotransferase step, but their carbon skeletons enter separate pathways. L-Valine is glucogenic and yields succinyl-CoA; L-leucine is ketogenic and yields acetoacetate plus acetyl-CoA; L-isoleucine is both glucogenic and ketogenic and yields acetyl-CoA plus propionyl-CoA. This distinction changes the caloric and nitrogen balance in parenteral amino acid solutions and the ideal ratio in animal feed formulations.

At comparable additions, L-valine has higher aqueous solubility than L-leucine, which reduces precipitation risk in concentrated liquid supplements. However, its crystalline bulk density and particle-size distribution differ. Dry premixes containing both L-valine and L-leucine can segregate unless granulated or blended with a compatible carrier. The lower hydrophobicity of the isopropyl side chain compared with leucine’s isobutyl side chain also changes packing and dissolution behavior. Published dissolution-rate data for specific commercial granulations is limited.

Feed-grade L-valine is incorporated into least-cost formulations to correct digestible valine deficits in cereal-soybean diets. In poultry finisher diets, valine is commonly expressed relative to standardized ileal digestible lysine; published requirement ratios are strain- and energy-dependent. Production-scale blending on double-ribbon mixers should avoid addition sequences that place coarse crystalline valine directly on soybean meal fines because electrostatic attraction and particle-size mismatch can produce localized pocket concentrations. Granulated or premixed product with a bulk density matching the carrier is preferred when mixer run time is shorter than 8–10 minutes. The product does not require nitrogen blanketing under normal warehouse conditions at relative humidity below 65 %, although storage above 60 % RH can increase caking in fine crystal grades.

For chemically defined cell culture, the low-endotoxin grade is dissolved in basal media at neutral pH. L-Valine depletion in CHO and HEK293 perfusion culture causes cell cycle arrest at the G1/S boundary; therefore the amino acid is included in feed concentrates at concentrations derived from metabolic flux analysis. Solubility is seldom limiting in feeds at 2–8 °C, but concentrated 50× acidic or neutral stock solutions should be checked for crystal re-formation if pH approaches the isoelectric point of 5.96.